Sanofi SA, of Paris, and the Joslin Diabetes Center, of Boston, reported that they have established a collaboration that will focus on four key areas within diabetes and related metabolic disorders to identify potential new biologics or small drug candidates for the treatment of late complications of diabetes and new insulin analogues with more targeted efficacy...Sanofi has options to commercialize the results of the research...Both parties will have access to intellectual property for internal

Horizon Pharma Inc., of Deerfield, Ill., and Mallinckrodt LLC, the pharmaceuticals business of Covidien LLC, of Dublin, Ireland, signed a U.S...Horizon granted Mallinckrodt the right to co-promote Duexis to targeted physicians in the U.S

MenHibrix is to be given in a four-dose series at 2, 4, 6 and 12 through 15 months of age...in April 2011, and has been approved in more than 45 other countries since then...BCG is used to prevent serious complications of tuberculosis infection, notably for infants and children living in First Nation and Inuit communities at high risk for tuberculosis outbreaks, and it is not widely used

Astellas Pharma Inc., of Tokyo, and the Drugs for Neglected Diseases initiative (DNDi) agreed to collaborate on drug discovery research for leishmaniasis, Chagas disease and sleeping sickness...Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Polyphor Ltd., of Allschwil, Switzerland, inked a research collaboration and license agreement to apply Polyphor's MacroFinder drug discovery technology to identify and optimize macrocyclic drug candidates addressing therapeutic targets selected by

Mylan Pharmaceuticals Inc., of Pittsburgh, settled a dispute with Teva Pharmaceuticals USA Inc., part of Teva Pharmaceutical Industries Ltd., of Jerusalem, over litigation brought by Mylan against the FDA related to Mylan's abbreviated new drug application for Modafinil tablets, 100 mg and 200 mg...The agreement with Teva stipulates that Mylan may launch its Modafinil tablets on Aug. 10, prior to the expiration of the 180-day marketing exclusivity period granted to Teva

Ferring Pharmaceuticals SA, of Saint-Prex, Switzerland, said it donated $10 million to support research at the Salk Institute for Biological Studies in La Jolla, Calif., including research on the role that TAM receptors play in immune regulation

Boehringer Ingelheim GmbH, of Ingelheim, Germany, said the labeling of Pradaxa (dabigatran etexilate mesylate) 150-mg capsules was updated to affirm that twice-daily use of the drug was superior to warfarin in reducing ischemic and hemorrhagic strokes, based on the results of the pivotal RE-LY trial conducted in 18,000 patients with nonvalvular atrial fibrillation (NVAF...Additionally, Boehringer recently launched a Phase II trial of the GLORIA-AF patient registry, designed to better characterize

Subsequently, Cytochroma regained the rights to all indications in Asia and the U.S...to lunacalcipol, the first compound in a new class of vitamin D hormone analogues...Royer Biomedical Inc., of Frederick, Md., received FDA approval to proceed with human testing of AppliGel-G (gentamicin) in the management of diabetic foot ulcers

Forest Laboratories Inc., of New York, issued a statement in response to a Form 13D filing from entities affiliated with activist shareholder Carl Icahn stating an intention to nominate a minority slate of candidates to the company's board

Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, said they received a positive opinion from the European Medicine's Agency medicinal committee recommending approval of Jentadueto, a product containing DPP-4 inhibitor linagliptin and metformin in a single tablet for twice-daily dosing, to improve glycemic control in adults with Type II diabetes who are inadequately controlled on maximally tolerated metformin alone or are already being treated with the

Almirall recently signed a deal granting Menarini Group, of Florence, Italy, rights across a majority of European Union member states, as well as Russia, Turkey and other CIS countries, where it will market the drug as Bretaris Genuair...In addition to BMS, the collaboration comprises 10 cancer-research institutions, including the Dana-Farber Cancer Institute, Johns Hopkins Kimmel Cancer Center and Memorial Sloan-Kettering Cancer Center...The company said it will respond to the agency as quickly as

If approved by the European Commission, the drug would offer a single-tablet treatment option, taken twice-daily, for adults with Type II diabetes who need to improve control of their blood glucose

to reduce the risk of blood clots in the legs and lungs of people who have just had knee or hip replacement surgery and to reduce the risk of hemorrhagic and thrombotic strokes as well as other blood clots in individuals with atrial fibrillation not caused by a heart valve problem

The submission is supported by clinical trials involving more than 11,000 patients treated for up to four years and several ongoing studies, including the EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) trial, which will evaluate cardiovascular endpoints following treatment with alogliptin to comply with the FDA's cardiovascular safety guideline

Novo Nordisk A/S, of Bagsvaerd, Denmark, said the FDA approved Levemir (insulin detemir [rDNA origin] injection) for use in children, ages 2 to 5, with Type I diabetes

H. Lundbeck A/S, of Copenhagen, Denmark, and not-for-profit research organization CHDI Foundation Inc., of Deerfield, Ill., said they are collaborating to investigate a targeted therapy for Huntington's disease...Inc., of Whitehouse Station, N.J., said the FDA approved a labeling update for HIV-1 drug Isentress (raltegravir) film-coated tablets to include 156-week data from the STARTMRK study showing that the integrase inhibitor in combination therapy demonstrated long-term viral suppression, a

Under the agreement, BMS will fund research efforts at the university's School of Life Sciences to identify and validate targets in oncology and immunoscience...In separate news, BMS said the FDA approved its biologics manufacturing facility in Devens, Mass., for commercial production of arthritis drug Orencia (abatacept

Stiefel, of Research Triangle Park, N.C., part of GlaxoSmithKline plc, said the FDA approved a new drug application for Fabior (tazarotene) foam 0.1 percent, a topical formulation of a retinoid to treat acne vulgaris in patients 12 years and older

Watson Pharmaceuticals Inc., of Parsippany, N.J., said that its subsidiary, Watson Laboratories Inc., filed an abbreviated new drug application with the FDA for Mesalamine delayed-release tablets 1.2 g. The product is a generic version of Lialda, by Shire Development LLC, a division of Shire plc, of Dublin, Ireland.